Conclusion: Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
introduction KRAS exon 2-4 and NRAS exon 2-4 mutations (=RAS mutations) are found in ∼50% of metastatic colorectal cancer (mCRC) tumors and exclude affected patients from epidermal growth factor receptor (EGFR)-directed therapy [1] [2] [3] . Besides their negative predictive value, RAS mutations may also carry distinct prognostic information [4] [5] [6] . Some studies suggest that EGFR inhibition may even be detrimental in patients with RAS-mutant mCRC [1, 7] maybe due to interaction with the chemotherapeutic backbone [8] [9] [10] . Furthermore, low prevalence of the different RAS mutation variants limits conclusions concerning the impact of different subtypes of RAS mutation on prognosis so far.
BRAF V600E mutation occurs in ∼5%-10% of mCRC tumors [1, 5, 11] . Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12] , associated with rapid clinical deterioration after progression to initial therapy [12] . However, promising data with combination regimens as well as experimental treatment options may lead to routine assessment of this mutation in mCRC in the near future [5, 13] .
This analysis was designed to explore the prognostic impact of mutations in RAS genes, their subtypes and BRAF on outcome of mCRC patients treated within randomized trials of the AIO colorectal cancer study group. With respect to potentially confounding factors of EGFR-based treatment, patients receiving EGFR-targeted agents as first-line therapy were not included.
patients and methods studies
This analysis is based on individual patient data from five first-line trials in mCRC: FIRE-1 [14, 15] , FIRE-3 (only bevacizumab-arm) [2, 16, 17] , AIO KRK 0604 [18] , AIO KRK 0207 [19] and RO91 [20] . Protocols, responsibilities, declarations of Helsinki, ethical approvals, definitions, treatment schedules and results of the studies were reported previously [2, 14, [18] [19] [20] .
molecular assessment
Patients were derived from molecularly characterized subsets of the original study-populations (that were evaluated for KRAS exon 2 mutations and BRAF V600E mutation). FIRE-1, FIRE-3 and AIO KRK 0207 were additionally analyzed for mutations in KRAS exon 3-4 as well as NRAS exon 2-4. Methods of testing have been reported in previous publications [15] [16] [17] [18] [19] 21] . Patients were only included into the analysis if a single specified (i.e. including base-exchange) RAS/BRAF mutation or no RAS/BRAF mutation was present.
patient data
The following information was assessed for all patients: sex, age, mutation information, treatment, ECOG, location of primary tumor (colon versus rectum), metastatic spread, prior adjuvant chemotherapy, progression-free survival (PFS), overall survival (OS) and response information.
PFS and OS
PFS was defined as interval between randomization or registration and progression or death from any cause. OS was defined as interval between randomization or registration and death from any cause. For AIO KRK 0207, PFS and OS were calculated from the initial registration (start of induction Table 1 .
Patients and studies
Original study 72 (35.6) a n.a.
13 (6.4) n.a., not assessed; FP, fluoropyrimindine; percentages in parentheses indicate percentage of molecular subgroups within the respective study (-arm 
results
For this analysis, data of 1239 patients were available. Distribution of patients across studies according to molecular characteristics is summarized in Table 1 .
mutations
Of 1239 analyzed tumors, in 664 tumors (53.6%), no mutation was detected, whereas 462 tumors harboring KRAS (37.3%) mutations and 39 NRAS (3.1%) mutations were found. Additionally, a total of 74 tumors (6.0%) were carrying BRAF V600E mutations (supplementary Table S1 , available at Annals of Oncology online). Distributions of baseline characteristics in molecular subgroups are summarized in Table 2 .
prognostic role of KRAS, NRAS and BRAF mutation PFS and OS were significantly influenced by molecular subgroups ( Figures 1A and B and 2A and B). Univariate and multivariate comparisons of PFS and OS in patients with mutant tumors (KRAS, NRAS, BRAF) versus patients with non-mutated tumors revealed a negative prognostic effect of KRAS and BRAF mutations (Figure 2A and B) . Interestingly, the negative prognostic role of KRAS and BRAF mutations was consistently observed across different treatment regimens (subgroups of irinotecan-and oxaliplatin-treated as well as in bevacizumab-and non-bevacizumab-treated) (Figure 2A and B).
prognostic role of single RAS mutation variants
The median PFS of patients with KRAS exon 2 mutant tumor subtypes ranged from 8.8 [95% confidence interval (CI) 7.6-10.0] months (G13D mutation) to 10.5 (95% CI 9.0-11.9) months in (G12D variants). The median OS widely ranged between 16.8 (95% CI 15.6-18.0) months (G12C) and 25.2 (95% CI 22.2-28.2) (G12D variants) ( Figure 1C and D) . Besides KRAS exon 2 variants, KRAS mutations A146T (n = 18) and Q61H (n = 17) as well as NRAS mutation G12D (n = 11) were separately evaluated for efficacy end points, all other variants were less frequent (supplementary Table S1 , available at Annals of Oncology online).
Comparisons of PFS and OS (univariate and multivariate) of patients with mutation variants to patients with nonmutated tumors revealed the KRAS exon 2 G12C-variant (n = 28) to correlate with inferior OS compared with non- 
discussion
The present analysis was motivated by the limited clinical data regarding the prognostic impact of RAS mutation variants in patients with mCRC receiving first-line systemic treatment without EGFR-targeted therapy. Our analysis comprises data of 1239 patients and therefore represents one of the largest datasets available. KRAS (37.3%) and NRAS (3.1%) mutations were a little less frequent in our cohort compared with other series. [1, 22] . Selection of KRAS exon 2 wild-type for inclusion in the FIRE-3 trial as well as lack of testing for KRAS exon 3-4 and NRAS exon 2-4 in AIO KRK 0604 and RO91 may have contributed to this result. The lack of testing in these two studies might cause a small negative bias on outcome of patients with unmutated tumors.
Baseline characteristics compared between molecular subgroups reflected more aggressive disease in patients with mutated tumors (in particular in patients with BRAF-mutant mCRC). BRAF mutation seemed associated with female sex and tumor location (colon). These results confirm previous observations [23] .
PFS of patients evaluated by molecular subgroups demonstrated a strong negative prognostic effect of BRAF mutation (HR 2.19, P < 0.0001) as well as a smaller, but also significant negative effect of KRAS mutation, both compared with non-mutated tumors (HR 1.2, P = 0.03). The differences in outcome associated with molecular subtype were pronounced in OS. Of note, the median OS reported in patients with non-mutated tumors was 26.9 (95% CI 25.2-28.5) months. Taking into account that not all patients had access to EGFR-targeted agents since these were partly unavailable at the time of study conduct of FIRE-1/RO91, this result compares well with recent reports of first-line treatment in mCRC [5, 24] . Outcome of patients with KRAS or BRAF-mutant mCRC demonstrated significantly shorter medians of OS: 21.0 (18.5-23.5) and 11.7 (9.7-13.6) months, respectively, translating to HRs of 1.41 (P < 0.001) for KRAS and 2.99 (P < 0.001) for BRAF. Availability of later-line treatment (i.e. EGFR-targeted agents) in patients with non-mutated tumors might have impacted on OS for those patients. However, the also present differences in PFS in patients with non-mutated tumors compared with patients with KRASmutant mCRC support the hypothesis that KRAS is a prognostic factor per se and differences in outcome are not only mediated by a subset of patients receiving later-line EGFR-inhibitors. The number of patients with NRAS-mutant tumors in this dataset was probably too small to allow for significant effects on outcome.
In this pooled dataset, the prognostic effect of molecular subgroups (i.e. KRAS and BRAF mutation) in comparison with non-mutated tumors was consistently observed in all subsets of patients being treated with irinotecan-or oxaliplatin combinations as well as in bevacizumab-or non-bevacizumab-treated patient. Considering that microsatellite-instable tumors are rare in stage IV mCRC, these findings compare well with a recent analysis of the adjuvant PETACC-8-trial that identified KRAS and BRAF mutations as prognostic markers in microsatellitestable (but not microsatellite-instable) tumors [25] . Further classification of mCRC might be seen in differentiation of leftsided versus right-sided primary tumor location, probably being a surrogate for molecular profiles that have not been understood in full extent [26] . Unfortunately, primary tumor location was not recorded during study conduct for the majority of patients in this cohort and cannot be taken into account for our analysis.
KRAS exon 2 mutation variants were associated with heterogeneous outcome concerning OS as well as PFS. The G12V mutation variant, representing one of the most frequent subtypes, was associated with a significantly worse PFS compared with patients without any mutation (HR = 1.48, P = 0.02). OS was also inferior -however not significant-in G12V and G13D 1 subtypes, and significantly inferior in G12C mutations variants compared with patients with non-mutated tumors. This observation supports the hypothesis that KRAS exon 2 mutation variants are associated with a differing spectrum of clinical outcome [4, 8, 27] . It might be speculated that the reason for differing outcomes could be mediated by differing activation of KRAS-depending pathways by distinct mutation variants, as suggested previously with high baseline activation and potentially aggressive biology in G12C variants [28] . In addition, the poor outcome of patients with G12C mutant mCRC might be of clinical relevance as allele-specific inhibitors may provide therapeutic options in the future [29, 30] . In this context, also the mutation rate of KRAS could be a factor that impacts significantly on prognosis of KRAS-mutant mCRC [31] . Unfortunately, this information is not available for our cohort.
In general, despite high data quality, pooled datasets of different randomized trials may always lead to cohorts with study-specific bias. Although multivariate models can adjust calculations for some (obvious) factors, retrospectively evaluated, pooled data invoke uncertainties. Pooling data from five studies has enlarged the number of some mutation variants (i.e. NRAS as well as KRAS exon 2 mutation variants) to a level that consecutively enabled survival analysis. However, absolute numbers in these subgroups are still unsatisfactory and the analyses appear underpowered to allow for definite conclusions, especially in rare mutation variants. In particular, false-negative results cannot be excluded as potential limitations in this setting. Given that some biomarkers (i.e. KRAS mutation variants) were identified as potential prognostic markers, validation of our findings within alternative study-sets appears justified.
In conclusion, our data suggest that mutations in KRAS and BRAF are associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. Whereas role of chemotherapy and treatment with or without bevacizumab did not affect these findings, KRAS exon 2 mutation variants differed, with G12C being associated with shorter OS when compared with patients with non-mutated tumors, while G13D mutations were showing a similar trend.
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